Moxetumomab pasudotox

Capillary Leak Syndrome and Hemolytic Uremic Syndrome

Capillary Leak Syndrome (CLS)

• Capillary Leak Syndrome (CLS), including life-threatening cases, occurred in patients receiving LUMOXITI. Delay dosing or discontinue LUMOXITI as recommended. 

Hemolytic Uremic Syndrome (HUS)

• Hemolytic Uremic Syndrome (HUS), including life-threatening cases, occurred in patients receiving LUMOXITI. Discontinue LUMOXITI in patients with HUS. 

Patient Counseling Information

• LUMOXITI

Medication Guides

Patient Medication Guide - LUMOXITI

Package Inserts

Moxetumomab pasudotox